YES-ERACE Curriculum for Reducing Youth Violence
(YES-IDEAS Trial)
Trial Summary
What is the purpose of this trial?
This trial tests the YES-ERACE program, which helps middle school students from diverse backgrounds create projects to fight racism. By participating, students are expected to feel more empowered, develop better attitudes towards different races, and reduce violent behaviors.
Will I have to stop taking my current medications?
The trial information does not specify whether participants need to stop taking their current medications.
What data supports the effectiveness of the YES-ERACE treatment for reducing youth violence?
The YES-ERACE treatment may be effective in reducing youth violence as similar programs, like the Aban Aya Youth Project, have shown success in limiting violent behaviors among students. Additionally, youth empowerment strategies, such as those used in the Youth Empowerment Solutions program, have demonstrated positive effects on reducing violence and improving community outcomes.12345
How does the YES-ERACE treatment differ from other youth violence prevention treatments?
Eligibility Criteria
This trial is for middle school students in grades 6-8 who are part of after-school programs at six schools within the Genesee County Intermediate School District. Participants must agree to join; those who don't or whose parents refuse cannot participate.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Adaptation Phase
Adapting the YES curriculum to integrate modules from the Learning for Justice curriculum and piloting the revised curriculum
Testing Phase
Testing the effects of the YES IDEAS curriculum on youth empowerment, racism attitudes, and violent behavior in a group-randomized trial
Follow-up
Participants are monitored for sustainability of YES IDEAS effects on empowered outcomes and behavior changes
Treatment Details
Interventions
- YES-ERACE (Behavioral Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Michigan
Lead Sponsor
National Institute on Minority Health and Health Disparities (NIMHD)
Collaborator